Upcoming meeting: Tumor Models, London, January 2013

The path to successful clinical development of oncology drugs starts with using predictive tumor models. This is easier said than done. 

The organizers of the Tumor Models meeting in London (January 29-31, 2013) have assembled a roster of speakers from AstraZeneca, Eisai, Roche, MedImmune, Genentech, Sanofi and others to discuss tumor models used at these companies, optimization of traditional models, and explore alternative models and methods to better predict drug efficacy.

Some of the highlights from the agenda include:

• Hear how Roche are designing immunocompetent tumor models to better predict patient response in the clinic
• Learn how MedImmune use their syngeneic models to improve the predictive value of preclinical data
• Understand how AstraZeneca are using in silico tumour modelling for assessing multiple parameters at once
• Improve early drug development by learning how Bayer model biomarke and human tumour growth between animals and humans
• Listen to world renowned academic leaders talk about cutting edge research related to xenograft models that better predict drug efficacy

Here is the impressive lineup of speakers:

Current Trends in Tumour Models; Challenges and Opportunities

Dorothee Foernzler, Translational Medicine Expert, BoehringerIngelheim

Orthotopic Tumour Xenografts as a Model for Improved Clinical Relevance

Sharon Pearsall, Team Leader, AstraZeneca

Ensuring your Chosen Tumour Model is Clinically Relevant for Target Cancers to Avoid Pursuing False Positives

Prash Krishna, Director, Eisai

Developing 3D Organotypic Invasion Assays to Improve the Study of Tumour Invasion

John Marshall, Reader in Tumour Biology, Barts Cancer Institute

Designing Preclinical Tumour Models to Better Predict Patient Response in the Clinic

Patricia Vrignaud, Principal Investigator, Sanofi

The Use of Syngeneic Models in Immune Mediated Therapies of Cancer

Richard Sainson, Oncology Team Leader, MedImmune

Mouse Models for Preclinical Testing of Novel Cancer Therapeutics: Translation into the Clinic, Fit-for-purpose Design and Practicability of New Approaches

Katharina Wartha, Principal Investigator, Roche

3D Tumour Models as an Approach to Describe the Molecular Mechanisms Underlying Growth

Umber Cheema, Research Fellow, University College London

Developments and Advancements of in silico Tumour Models for Assessing Multiple Parameters at Once

Tao You, Physiological Modeller, AstraZeneca

Establishing 3D Spheroid Cultures from Breast Cancer Patient Derived Tumour Samples to Derive Novel in vivo Models

Adam Nopora, Principal Investigator, Roche

Devising Tumour Models that Better Predict Drug Efficacy

Lorenza Wyder, Senior Labhead, Actelion

Developing Genetically Engineered Breast Cancer Models  that Reflect Patient Heterogeneity; Squaring the Circle

Matt Smalley, Principal Investigator, University of Cardiff

Tumour ex vivo Cultures as a Method to Model Drug Response

Elad Katz, Research Fellow, University of Edinburgh

Optimising Early Drug Development by Modelling Biomarkers and Human Tumour Growth between Animals and Humans

Philip Groth, Research Scientist, Bayer

Advances in Imaging Tumour Cell Proliferation in Animal  Models to Accelerate the Development of Therapeutic Strategies

Simon Walker-Samuel, Senior Research Associate, UCL

Practical Approaches to Integrating Novel Imaging Techniques with Existing Tumour Models to Improve Data Sets Moving into the Clinic

Francois Lassailly, In Vivo Imaging Specialist, Cancer Research UK

Cell-Based Imaging as an Approach to Discover and Build Confidence in Predictive Markers Prior to the Clinic

Simon Robinson, Principal Investigator, Institute of Cancer Research

In addition, two workshops have also been planned:

 

Novel Imaging Approaches for Tumour Models; Challenges and Opportunities

Workshop leader: Francois Lassailly, In Vivo Imaging Specialist, Cancer Research UK

Exploring Xenograft Models to Optimise Data Sets that Address Drug Efficacy

Workshop leader: Patricia Vrignaud, Research Investigator, Sanofi

..
 
Register for this meeting at http://tumour-models.com/

..